Anti Inflammatory News and Research

RSS

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

AlphaRx Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment.

25 Mar 2011

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.

25 Mar 2011

Modified Atmosphere Packaging can retain polyacetylenes levels in carrots

Polyacetylenes are natural products found in certain plants that have been related to a reduction in the risks of developing diseases such as certain types of cancers and other important diseases.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Strong 'innate immunity' effective in chikungunya patients

Chikungunya is transmitted by mosquitoes of the genus Aedes. The disease is spreading in the world and periodically sparks new outbreaks. Africa, Asia, the Indian Ocean and even Southern Europe are now affected.

23 Mar 2011

Anacor enters $30 million loan agreement

Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.

21 Mar 2011

New insight into Duchenne muscular dystrophy

Armed with a zebrafish model of Duchenne muscular dystrophy and a library of 1,200 chemicals already approved for human use, researchers at Children's Hospital Boston have identified a compound that reverses the loss of muscle structure and function associated with DMD, seemingly by compensating for the loss of a critical protein.

19 Mar 2011

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

Although it has been known for some time that vitamin A deficiency is linked with an impaired ability to resist infections, exactly how vitamin A and its metabolites contribute to the immune response is not well understood.

18 Mar 2011

Eating fish protects from blindness: Study

According to latest study fish that is rich in omega 3 fatty acids significantly lowers the risk of developing age-related macular degeneration that leads to blindness. The study was published in the Archives of Ophthalmology.

17 Mar 2011

Eating fatty fish reduces blindness risk from AMD: Study

New research has shown that consuming omega-3 fatty acids that are most commonly found in oily fish such as tinned salmon and tuna, could prevent the onset of age-related macular degeneration (AMD), a condition that leads to the gradual loss of vision. The required amount may be as low as one to two portions of fish a week that can reduce the risk of sight loss by up to 42 per cent in older women, according to a new study. Earlier results have shown similar benefits in men. Omega 3, whose common form in food is Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) can also be taken as a supplement.

16 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Specific inflammatory factor may be responsible for aortic stenosis development

Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.

15 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

HDL cholesterol structure finding could help explain cardioprotective effects

University of Cincinnati researchers have determined the structure of human HDL cholesterol and say the finding could help explain how this "fat packet" protects against cardiovascular diseases, including heart attack and stroke.

14 Mar 2011